Drugs / APVO210
last change Jun 2020 re-read 3 minutes ago

APVO210

Developed for
psoriasis · ulcerative colitis
Investigated by
Aptevo Therapeutics

Trials 1

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03768219 Mar 2019 → Jun 2020 psoriasis, ulcerative colitis Aptevo Therapeutics Terminated No outcome recorded Stop: Business

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as APVO210 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03768219 ↗